Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA.
Breast J. 2012 Jan-Feb;18(1):41-51. doi: 10.1111/j.1524-4741.2011.01175.x. Epub 2011 Nov 20.
Breast cancer that lacks expression of estrogen/progesterone receptors and overexpression of the human epidermal growth factor receptor2 (HER2), i.e. triple-negative breast cancer (TNBC), is not amenable to current targeted therapies and carries a poor prognosis. This review discusses the natural history of TNBC and published literature in the relevant treatment landscape, with a focus on newer therapies. Compared with other subtypes of breast cancer, TN tumors have higher response rates to neoadjuvant chemotherapy; however, this advantage is not clearly translated into the metastatic setting and has not improved these patients' overall survival. Numerous cytotoxic and targeted strategies have demonstrated efficacy or are under investigation. Strategies showing promise in this difficult-to-treat group of patients include cytotoxic therapy with platinum-containing agents, ixabepilone, and novel targeted approaches such as poly(ADP-ribose) polymerase inhibitors.
缺乏雌激素/孕激素受体表达和人表皮生长因子受体 2（HER2）过表达的乳腺癌，即三阴性乳腺癌（TNBC），不能适应目前的靶向治疗，预后不良。这篇综述讨论了 TNBC 的自然病史和相关治疗领域的已发表文献，重点介绍了新的治疗方法。与其他类型的乳腺癌相比，TN 肿瘤对新辅助化疗的反应率更高；然而，这一优势在转移性疾病中并没有明显体现，也没有改善这些患者的总生存期。许多细胞毒性和靶向策略已被证明有效或正在研究中。在这一治疗困难的患者群体中显示出前景的策略包括含铂药物、伊沙匹隆的细胞毒性治疗，以及多聚（ADP-核糖）聚合酶抑制剂等新型靶向方法。
